Publication | Open Access

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Cutaneous T-cell LymphomaLymphoid NeoplasiaMedicinePathologyMogamulizumab Versus VorinostatDermatologyImmunotherapyOncologyPhase 3